2022-501250-12-01RecruitingPhase 2
Clinical study to evaluate the safety and tolerability of SPVN06 (novel gene therapy) in a subset of patients with rod cone dystrophy (RCD).
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Sparingvision
- Enrollment
- 17
- Locations
- 1
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Daniel Chung
Scientific
Sparingvision
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
A study to assess the safety, tolerability, uptake and efficacy of VMX-C001 in healthy volunteers.2023-507059-32-00VarmX B.V., VarmX B.V.48
Recruiting
Phase 1
Study of safety, tolerability, pharmacokinetics and pharmacodynamics of MSD-001 in healthy participants2024-512939-67-00Mindstate Design Labs Inc.68
Recruiting
Phase 1
A study to evaluate the Safety, Pharmacokinetics, and Activity of Subcutaneous Cevostamab (BFCR4350A) in Patients with Relapsed or Refractory Multiple Myeloma (CAMMA 3)2023-503404-89-00Genentech Inc.45
Completed
Phase 1
Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia2023-508819-23-00Hutchmed Ltd.22
Recruiting
Phase 1
A phase I trial evaluating the safety, tolerability, and pharmacokinetic profile of INP12 in patients with advanced solid tumors.2024-518126-32-00Innoup Farma S.L.70